Credits: Canva
Is your teenager skipping breakfast? Why is that happening and what can you do? As per the data from the Centers for Disease Control and Prevention (CDC), which surveyed adolescent health and well-being found that 1 in 4 students in high school ate breakfast, which means 3 in 4 high school students are not eating their breakfast. This data is as per the 2023 survey.
The report describes a 10-year long trend and also recent changes among the two years. The study delved deeper into adolescents' dietary, physical activity and sleep behaviors. The study is also based on a national youth risk behavior survey of a representative sample of students from grade nine to 12.
The study found that while high school students drank slightly less soda and sports drinks and consumed more water, other healthy eating habits declined. In 2023, only 27% of students ate breakfast every day in the past week. The numbers were even lower for female students, with just 22% eating breakfast daily, compared to 32% of male students. Boys were also more likely to eat fruits and vegetables daily and drink water at least three times a day. Poor mental health and lack of physical activity have also been linked to skipping breakfast.
The other findings included a survey across 10-year period, where a decrease in the percentage of students eating fruits from 65% to 55%, eating vegetables, from 61% to 58%, and having breakfast daily from 38% to 27% was noted.
However, there was a positive trend among this, which was in children drinking plain water at least three times a day, which increased from 49% to 54% from when the survey began in 2015.. There were fewer students who also said that they drank soda in 2023 than in 2013. On an average, in 2013, around 22% students avoided soda, whereas in 2023, 31% students avoided it.
The report also emphasized that a healthy diet, along with daily physical activity and sufficient sleep further contributes to a healthy lifestyle. “The 10-year trends from 2013 to 2023 also show a decline in healthy dietary, physical activity, and sleep behaviors,” the survey reported.
While there is no one straightforward answer to it, psychologists and those who study children, believe that for many high school going kids, it is the easiest time to skip a meal. This is because they are caught between rushing to school, or not just that hungry in the morning. So for them, to sit down to have a breakfast may seem hassle and something they would have to take time out from their busy schedule. They at this age also prioritize their extra-curricular activities.
There has also been a shift in their circadian rhythm, and most teens cannot fall asleep before 11 pm, or even at midnight. Which means they wake up tired and struggle to do things right in the morning, which is why they choose to skip breakfast or give extra minutes to any other activities.
There is of course another, more popular reason, to lose weight. While experts and studies, like the one published in the Journal of Nutrition that found skipping breakfast leads to higher levels of hunger hormones, the students still feel the need to do this. However, it could lead to a slow metabolism, prompt the body to conserve energy and burn fewer calories, weight gain and deprive yo off the essential nutrients like calcium, iron, and vitamin D.
Without a morning breakfast, your blood sugar might drop too, which can increase irritability and stress, along with including the risk of depression in teenage.
Credit: AI
Your eyes may explain a lot about how your brain handles attention. A new Indian study suggests that tiny fluctuations in the pupils may provide a physiological clue to attention related differences in children with ADHD.
Researchers from the Indraprastha Institute of Information Technology Delhi analysed eye-tracking data from 50 children aged 10 to 12, including 28 children with combined-type ADHD and 22 without a neurodevelopmental diagnosis. These findings were published in Scientific Reports.
Instead of just looking at the size of the pupils, researchers examined how pupil responses shifted from one trial to another while children performed a working-memory task.
During the experiment, children watched dots appear on a grid and had to remember their positions while ignoring distractions. An eye tracker recorded their pupil diameter 1,000 times per second.
After accounting for age, IQ and memory-task difficulty, the researchers estimated that unmedicated children with ADHD had about 23% greater trial-to-trial variability in their pupil responses than children in the control group.
Among the unmedicated children with ADHD, greater pupil variability was also associated with poorer accuracy on the task.
The pattern was, however, more complicated. Within individual trials, pupil variability was actually lower in the ADHD group. This suggests that different measures of pupil dynamics may capture different aspects of attention and brain activity.
Also read: Increased Screen Timings Have Lead to ADHD: Key Symptoms
The researchers also looked at 17 children with ADHD who completed the task both after taking their usual methylphenidate medication and after stopping it for 24 hours.
When the children were taking medication, their pupils showed a stronger response during the task and less variation between trials. Their overall pupil-response pattern also became more similar to that of the control group. But the researchers caution against interpreting this as proof that medication normalising attention span.
Methylphenidate can itself influence physiological systems that affect pupil size, meaning the study could not completely separate the drug's direct effects on the pupils from changes related to attention.
Also read: Using AI Apps To Manage ADHD? How They Can Help And Why Experts Urge Caution
There is no single biological test for ADHD currently. Diagnosis involves clinical assessment, developmental history and behavioural symptoms across different settings and circumstances.
The study itself has several limitations. For instance, it was based on a small sample, used existing eye-tracking data and involved a controlled laboratory task rather than everyday environments like classrooms.
Although the statistical model found greater trial-to-trial pupil variability, the direct participant-level difference between the ADHD and control groups did not remain statistically significant after correction for multiple comparisons.
The researchers therefore describe pupil dynamics as a useful source of additional physiological information, rather than a diagnostic test.
First author Saumya Yadav said, "It is still too early to consider pupil measurements as a clinical diagnostic tool.”
Larger studies will need to determine whether these pupil patterns can reliably distinguish ADHD from other conditions and whether they remain consistent outside laboratory settings.
Credit: AI
A recent AI analysis of more than 400,000 Reddit posts about popular GLP-1 drugs like Ozempic, Wegovy, Mounjaro and Zepbound revealed several side effects that researchers may not have fully recorded in clinical trials.
The study, published in Nature Health, analysed 410,198 Reddit posts from May 2019 through June 2025. Researchers identified 67,008 people who self-reported using semaglutide or tirzepatide, with 43.5% reporting at least one side effect.
The findings do not prove that the drugs caused the symptoms. Instead, they did identify patterns in patients' own accounts that may need further investigation.
As expected, the analysis found gastrointestinal symptoms in majority. Among GLP-1 users who reported side effects, the most common were:
Researchers also found abdominal pain, reduced appetite, acid reflux, bloating, headache and dizziness among commonly reported symptoms.
But two groups of symptoms stood out as they may be less represented in existing clinical-trial data and drug information. They are reproductive symptoms and complaints associated with temperature.
Nearly 4% of people who reported side effects described reproductive symptoms, including irregular menstrual cycles, bleeding between periods and heavy bleeding.
GLP-1 drug users also described chills, feeling unusually cold, hot flashes and fever-like sensations.
Also read: GLP-1 Drugs Mounjaro, Zepbound Show Promise For 1 Billion With Sleep Apnea
The study was based on self-reported social-media posts, so researchers cannot establish whether semaglutide or tirzepatide directly caused menstrual changes, chills or hot flashes.
Other factors may also influence these symptoms. People taking GLP-1 drugs may experience substantial weight loss, changes in food intake, metabolic changes or other health changes that could effect these symptoms.
The researchers therefore describe these findings as safety signals, rather than confirmed adverse effects.
Clinical trials help in determining whether a medication is effective. They also help in identifying its potential side-effects. But once millions of people begin using a drug, patients may describe symptoms in everyday settings that were uncommon or not specifically investigated during trials.
Reddit provides researchers with a huge data collection of real-world experiences. AI can quickly scan hundreds of thousands of posts for recurring symptom patterns that would be extremely difficult to identify manually.
However, Reddit users are not representative of all people taking GLP-1 drugs. The researchers noted that the population studied was younger, more likely to be male and disproportionately based in the US.
The study does not provide evidence that people should stop Ozempic, Mounjaro or other GLP-1 medications. Instead, it shows how AI-assisted analysis of patient experiences could help in addition to traditional drug-safety trials and monitoring.
Common symptoms of GLP-1 medications remain nausea, vomiting, diarrhoea and constipation as they are backed by extensive research and clinical trials.
The newly highlighted symptoms, particularly menstrual and temperature-related changes, need clinical research to determine whether they are genuinely caused by the drugs.
Credit: AI
Globally renowned beauty and haircare brand L’Oréal is in the midst of a new legal battle in the US over allegations that it did not warn consumers possible potential cancer risks linked with its chemical hair-relaxer products.
Arizona Attorney General Kris Mayes filed a consumer fraud lawsuit against L’Oréal USA, its parent company and SoftSheen, accusing the companies of selling chemical hair relaxers without disclosing alleged links to ovarian and uterine cancers. Arizona is the first US state to bring such a lawsuit against L’Oréal over the products.
The lawsuit alleges that the products were primarily marketed to African American women and, in some cases, children.
The state is seeking damages and penalties, including warnings if the brand wants to keep selling the products.
Chemical hair relaxers are highly alkaline products designed to permanently straighten textured hair. They work by breaking and reforming the disulfide bonds in keratin, which gives hair its natural shape.
According to the Arizona lawsuit, some chemical relaxer products contain substances including phthalates, parabens, and other chemicals classified as probable carcinogens.
The complaint states that repeated use can increase exposure as these products are applied directly onto the scalp.
However, the presence of a potentially hazardous chemical does not establish that using a particular product will cause cancer. Cancer risk depends on factors including the substance, dose, duration, and route of exposure.
Also read: Prostate Cancer: What's Fact, What's Fiction
The legal action follows years of scientific research that examined links between chemical hair relaxers and cancers related to hormones.
A 2022 study from the US National Institutes of Health found that women who reported frequent use of chemical hair-straightening products had more than twice the risk of developing uterine cancer compared with women who did not use them frequently.
The researchers, however, found an association, not proof that hair relaxers directly caused these cancers.
Other research has also investigated possible links with ovarian and breast cancers, adding to concerns about repeated exposure to chemicals may cause serious health conditions.
Also read: Beyond Vaccines And Nutrition: Why Childhood Cancer Needs A Wider Conversation
According to Reuters, L’Oréal has rejected the allegations. A spokesperson for L’Oréal USA said that the company is confident in the safety of its products and considers that the claims lack legal and scientific merit.
The company said, “L’Oréal’s highest priority is the health and well-being of all our consumers. Our products are subject to a rigorous scientific evaluation of their safety by experts who also ensure that we strictly follow all regulations in every market in which we operate. We are confident in the safety of SoftSheen-Carson’s products and believe the allegations made in this lawsuit have neither legal nor scientific merit.”
L’Oréal also disputes the research underlying the litigation, saying the study cited by plaintiffs did not establish a causal connection between hair-relaxer use and the alleged health conditions and called for further research.
The Arizona lawsuit comes amid more than 12,000 similar lawsuits consolidated in a federal multidistrict litigation in Chicago involving L’Oréal, Revlon and other manufacturers. Trials in that litigation may start in 2027.
The current evidence does not mean that everyone who has used a chemical hair relaxer will develop cancer.
But repeated use is an area of ongoing scientific investigation. People who use these products can reduce unnecessary exposure by following product instructions carefully, avoiding application to irritated or damaged skin, and considering less frequent use or non-chemical alternatives.
© $2026 Times Horizon Private Limited